Health Protection Agency

Imperial College Innovations Limited

Secretary of State for Health and Social Care

Andrew Richard Gorringe

Andrew Robinson

Michael John Hudson

Karen Margaret Reddin

John Simon Kroll

Paul Richard Langford

Steven Anthony Rochford Webb

Keith Cartwright

Cliona Anne O'Dwyer

Philippa Bracegirdle

Keith Foster

Phillip Vincent

Denise Halliwell

A composition is provided comprisingouter membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. The composition is suitable for use in vaccines and for treatment of infection, particularly meningococcal infection, demonstrating a broad spectrum of protection. A number of preferred antigenic components are described and include antigenic proteins and proteoglycans derived from

Multicomponent meningococcal vaccine

An OMV preparation comprises OMVs having a sufficiently positive or negative surface charge to substantially prevent aggregation.

Stable compositions containing OMVs

A composition is prepared from a mixture of different vesicles, such as outer membrane vesicles (OMVs) and vaccines are based thereon. Another composition comprises in a single vesicle a combination of antigens and/or other vesicle components deriving from separate vesicles; again vaccines are prepared therefrom.

Outer membrane vesicles from gram negative bacteria and use as a vaccine

Methods and compositions for the treatment of microbial infection, and in particular meningococcal disease, comprise a commensalor an extract of a commensal. Further methods and compositions comprise commensalwhich express genes from virulent strains ofand/or heterologous gene products from non-neisserial sources. Such compositions are used in vaccine preparations for the treatment of microbial infection.

Neisserial vaccine compositions and methods

Methods and compositions for the treatment of microbial infection, and in particular meningococcal disease, comprise a commensalor an extract of a commensal. Further methods and compositions comprise conimensalwhich express genes from virulent strains ofand/or heterologous gene products from non-Neisserial sources. Such compositions are used in vaccine preparations for the treatment of microbial infection.

A composition comprising Transferrin binding proteins A and B is described (TbpA and TbpB). The composition is suitable for use in vaccines and for treatment of Gram negative bacterial infection, particularly meningococcal infection, demonstrating a broad spectrum of protection to a number of different bacterial pathogens. Also described are compositions comprising Tbps and other components, such as neisserial outer membrane vesicles and Cu,Zn-Superoxide dismutase. Methods for preparation of these compositions and their uses in vaccination against disease are further provided.

Growing community of inventors

Salisbury, United Kingdom

Andrew Richard Gorringe